TiGenix announces the grant of a US patent for ChondroMimetic

Leuven (Belgium) - August 30, 2010 - TiGenix (NYSE EURONEXT: TIG) announces that the US Patent & Trademark Office has granted a new patent for ChondroMimeticT.
This new patent (US 7,780,994) entitled 'Composite biomaterials comprising calcium phosphate materials, collagen and glycosaminoglycans' describes and claims the composition of and methods to produce a composite material comprising a triple coprecipitate of collagen, one or more glycosaminoglycans (GAG) and calcium phosphate. This patent forms the core protection of our ChondroMimetic product family.

The patent application was filed in the name of Cambridge Enterprise and exclusively licensed to TiGenix Ltd. (the former Orthomimetics Ltd). The patent was already granted in the United Kingdom, Singapore and China. Additional patent applications are pending in other jurisdictions around the world.
'I'm extremely pleased with the issuance of this important US patent on the eve of the launch of ChondroMimetic. We expect further geographical expansion of ChondroMimetic's intellectual property protection in the near future.' says Andrew Lynn, founder of Orthomimetics and co-inventor on the patent, now Chief Business Officer at TiGenix.

For more information, please contact:
Gil Beyen
Chief Executive Officer, TiGenix

Kris Motmans
Corporate Development and Communication

T: +32 16 39 60 60
investor@tigenix.com